Search PubMed⌕ Search

Biomedical subjects

C Cabrol

Publications and source records attributed to C Cabrol.

At least 109 records · Page 6Linked to original sources
PubMed1990

[Cardiac surgery in patients over 80 years of age. Experience of a series of 51 patients].

Between January 1980 and June 1988, 51 patients over 80 years of age underwent open heart surgery at the La Pitié hospital (26 women and 25 men; average age 82 +/- 2 years, range 80-90 years). The cardiac pathology was calcific aortic stenosis (AS) in 40 cases, associated with coronary artery disease in 7 cases, mitral valve prolapse in 3 cases, coronary artery disease alone in 6 cases [complicated by a post-infarction ventricular septal defect (VSD) in one patient] or associated with aortic regurgitation in 1 case, and degeneration of an aortic bioprosthetic valve in 1 case. Forty patients (78%) were in Stage III or IV or the NYHA Classification. There was no other major pathology associated with the cardiac disease. Aortic valve replacement (AVR) was carried out in 42 patients, with a bioprosthetic valve in 38 patients. This procedure was associated with coronary bypass surgery in 7 cases and carotid artery surgery in 1 case. A mitral bioprosthesis was implanted in 2 patients and mitral valvuloplasty was carried out in 1 patient. An isolated myocardial revascularisation procedure was performed in 5 cases; the VSD was closed in 1 case. The hospital mortality was 17.6 per cent (9 patients). All deaths were of cardiac origin. Eleven patients had no postoperative complications at all. The 3 year survival rate of those who survived surgery was 71 per cent. Of the current 31 survivors, 29 are in Stage I or II of the NYHA Classification. These results suggest that surgery can be offered to octogenarians with invalidating cardiac disease alone carrying a poor short term prognosis.

Actuarial Analysis↗
PubMed1990

[Value and results of coronary surgery before the repair of abdominal aortic aneurysm].

Seventeen polyarteriosclerotic patients underwent coronary bypass surgery before repair of an abdominal aortic aneurysm between December 1979 and November 1988 in the Cardiovascular Surgical Department of the Pitié Hospital. Sixteen patients had triple vessel disease and 1 patient had single vessel disease but with mitro-aortic valvular disease. The abdominal aortic aneurysm was asymptomatic in 9 cases. The diameter of the aneurysm was over 5 cm in all patients. The average time between the two operations was 6.3 +/- 5.4 months. One myocardial infarction was observed following the coronary bypass surgery. There were no complications related to the coronary artery disease or operative deaths after repair of the abdominal aortic aneurysm. Two late deaths occurred, one due to an aortoduodenal fistula and the other to extra cardiovascular causes. One patient underwent femoro-popliteal bypass surgery 4 years after repair of the aortic aneurysm. One patient had successful percutaneous transluminal angioplasty of an aorto-coronary venous bypass graft 8 years after its implantation. All the other patients are asymptomatic from the coronary and peripheral arterial points of view. The 7 year survival was 85.7 +/- 9.4 per cent. These results seem to justify immediate and late preventive myocardial revascularisation in patients with coronary artery disease requiring surgery prior to repair of an abdominal aortic aneurysm.

Aged↗
PubMed1990

[Intermediate and late changes in human cardiac graft].

Chronic rejection, the most serious complication in long-term survivors of cardiac transplantation, was studied in 5 cardiac grafts obtained at retransplantation and in 15 post-mortem studies of patients who had survived 3 months to 10 years after transplantation. The usual clinical presentation was cardiac failure. Coronary angiography was performed in several cases and showed narrowing and non-opacification of small arteries often accompanied by thrombosis. Histology showed three types of vascular rejection: the most characteristic one, usually observed after the 6th month, was a stenosing fibrous endarteritis; another type of rejection, occurring earlier, was associated with acute myocardial rejection and presented as an inflammatory arteritis; the third type of vascular rejection was accompanied by widespread atheromatous lesions. The significance and pathogenesis of these lesions are discussed with respect to the clinical context with electron microscopic and immuno-histochemical data.

Adult↗
PubMed1990

Intraoperative coronary artery endarterectomy with excimer laser.

Compared with continuous-wave lasers, excimer lasers exhibit several in vitro advantages: nonthermal ablation process and linear relation between the number of pulses and the depth of the crater. A 308 nm, 20 nsec pulse duration, 1 to 5 repetition rate laser was specifically designed for clinical application. At the time of cardiopulmonary bypass in 10 symptomatic patients, before bypass grafting, a 1 mm diameter core specifically ultraviolet-tipped fiberoptic scope was introduced via the coronary arteriotomy and placed upstream (seven patients) and downstream (three patients) in contact with the stenosis. Laser power was increasingly delivered up to the clearing of the stenosis or occlusion. Quality of angioplasty was controlled by calibration of the neolumen, cardioplegic solution output through the laser-treated segment, and an eighth day or sixth month coronary arteriogram. In the first three patients studied on the eighth day, all laser-treated coronary artery segments showed an early parallel-linked patent neolumen despite competitive bypass graft flow. In the patients studied after 6 months, all recanalized segments were patent except one; in one patient the venous graft was occluded, but the upstream laser angioplasty was patent. The main limitation of the method lies in the fact that laser coronary recanalization is confined to the fiber core diameter. We conclude that (1) excimer laser angioplasty may be safe and efficient during surgical procedure and (2) as catheter flexibility remains the most critical problem, we are now assuming an appropriate tool with a multifiber system that is suitable for intraoperative as well as percutaneous routes.

Aged↗
PubMed1989

[Should mild acute rejection of a cardiac graft be treated?].

With no additional therapy, mild acute cardiac allograft rejection progresses in 30 per cent of the cases towards moderate rejection. Three hundred mild rejections which occurred in 120 patients between May 1987 and May 1989 were studied and divided into 3 groups according to their treatment. Group I rejections (n = 108) were left untreated. In group II rejections (n = 186), the dose of oral corticosteroid therapy was increased, and in group III rejections (n = 6) major immunosuppressive treatment with methylprednisolone and antilymphocyte globulins (or Orthoclone OKT3) were initiated in view of the clinical and echocardiographic severity of the rejection. In the untreated group, 20 per cent of mild rejection progressed to moderate rejection, while 67 per cent are still at a mild stage in control myocardial biopsies. In group II, only 5 per cent of mild rejections have become moderate, and 19 per cent persisted as mild in control biopsies (p less than 0.05). The treatment of group III rejections resulted in complete disappearance of signs of heart failure and improvement of right and left ventricular contractile functions, proving that severe rejection was cured. This study demonstrates the effectiveness of increased oral corticosteroid therapy in minimal acute cardiac allograft rejections, without significant increase in infection or mortality rate. The principal reason for treating mild acute cardiac allograft rejections is to prevent their progression towards moderate rejections which require major immunosuppressive treatments and therefore have higher post-transplantation infection and mortality rates.

Adrenal Cortex Hormones↗
PubMed1989

[Heart transplant. Long-term follow-up].

The use of cyclosporin in the immuno-suppressive treatment has resulted in a spectacular improvement of the outcome of cardiac transplantation. But a number of complications, if they have become less severe, have note however totally disappeared. In order to detect them at an early stage, a strict monitoring is necessary. Systematic ambulatory visit are organized in the transplant center. In the interval between visits, a medical follow-up by cardiologist and attending physician is absolutely necessary.

Aftercare↗
PubMed1989

Circulatory Support 1988. Weaning and bridging.

After a patient has been supported with a circulatory assist device, the expected outcomes are weaning, bridging, or discontinuation of support. An early insertion of the device will avoid deterioration of the heart and other organs to an irreversible condition. Cardiac assistance for a minimum of 24 hours is recommended with a mild dose of anticoagulant. It is necessary to monitor the hemodynamic functions during circulatory support and weaning. Most of the mechanical devices are quite reliable, and complications during ventricular assist are easily managed. The patient should be in the same condition as in ordinary elective transplant candidate before transplantation. Patients with an artificial heart or ventricular assist device should not be on the priority emergency list for cardiac transplantation. Patients suffering from cardiogenic shock can be stabilized with a ventricular assist device to allow the heart to recover or be provided with other treatment. A circulatory support device can also be used as a bridge for patients awaiting a cardiac transplant.

Assisted Circulation↗
PubMed1989

Total artificial heart: survival and complications.

A total artificial heart was implanted in 28 patients as a bridge to transplantation. Mean time of mechanical support was 14.8 +/- 10 days. The 70-mL Jarvik-7 was used in 12 patients and the 100-mL Jarvik-7 in the remaining 16. No clinical thromboembolic complications occurred during implantation. There was no postoperative bleeding requiring operation. Both survival and the rate of complications were similar in the two Jarvik-7 groups. Eleven patients underwent successful transplantation, and 1 patient is still on mechanical support. Sepsis and multiple-organ failure were the most important causes of death. All patients receiving the total artificial heart for severe acute rejection after transplantation died of infection. Early implantation of the total artificial heart is advised in younger patients and in older patients with acute cardiac failure. The use of this device should be contraindicated in immunosuppressed patients because of the high risk of infection.

Adult↗
PubMed1989

Current problems in cardiac transplantation.

Since our initial orthotopic heart transplant (OHT) in 1968, the first in Europe, 1130 patients with ages ranging from 1 month to 66 years have been referred to us. The cause of irreversible myocardial damage was idiopathic cardiomyopathy in 74%, ischemic heart disease in 19% and left ventricular failure after valvular replacement in 7%. A total of 540 transplantations, 463 orthotopic, 40 heterotopic and 37 heart-lungs were carried out. Features of the early post-operative course include temporary (first week) cardiac instability treated by isoproterenol. Later complications included rejection (95%) and side-effects of immunosuppressive therapy; infection (83%), osteoporosis, malignancy, graft atherosclerosis (2%). Cyclosporine (Cy) was responsible for diastolic hypertension, renal dysfunction, hirsutism, hyperplasia of the gingiva, hepatic dysfunction, and seizures. The survival rate of the Cy-treated patients was 68% at 7 years. All survivors have virtually normal social and professional lives, included the longest survivor 14 years after the operation. Recently in 34 patients in acute irreversible cardiac failure and who cannot have a transplant in time, we implant a total artificial heart (TAH) type JARVIK 7 during a period from 1-150 days. There has been no mechanical failure, hemolysis or thrombo-embolism and only one right ventricular device malposition; 20 patients died before transplantation, 13 were successfully transplanted, 1 is still on the artificial heart. Heart transplantation, and TAH used as a bridge to transplantation are now an accepted therapeutic means for irreversibly cardiac failure in selected patients.(ABSTRACT TRUNCATED AT 250 WORDS)

Heart Transplantation↗
PubMed1989

Respiratory effects of the Jarvik-7 artificial heart.

In five anesthetized patients with a Jarvik-7 artificial heart, pulmonary volume displacements generated by cardiogenic oscillations were measured using an indirect spirometric method. Consequences on gas exchange were also evaluated during a 15-min period of apnea by use of a tracheal insufflation of pure O2 at a constant flow rate of 20 l/min. The Jarvik-7 artificial heart generated a mean pulmonary volume displacement of 105 +/- 29 (SD) ml/heart beat. After 15 min of apnea, arterial PCO2 (PaCO2) significantly increased from 29 +/- 5 to 47 +/- 6 (SD) Torr. PaCO2 increased by 0.8 Torr/min from the 5th to the 15th min of apnea. Mean arterial PO2, mean pulmonary shunt, mean O2 consumption, and mean metabolic production of CO2 did not change significantly during the apnea period. Because cardiac output was kept constant during the study, O2 transport was adequately maintained throughout the apnea period. In patient 1, where the period of apnea was continued for 60 min, PaCO2 progressively increased until the 45th min and then remained stable at 61 Torr during the last 15 min of apnea. This "plateau" corresponded to an alveolar ventilation of 3,907 ml/min, representing 69% of the alveolar ventilation calculated during conventional mechanical ventilation. In conclusion, the Jarvik-7 artificial heart provides a potent respiratory support through the cardiogenic oscillations it generates.

Adult↗
PubMed1989

Heart transplantation: update.

Clinical application of heart transplantation goes beyond 20 years of experience. The results achieved on the first 8,000 transplanted patients are impressive with a 70% survival rate at 7 years of follow-up. Indications for transplantation are less restrictive and include diabetics and patients older than age 60. Pulmonary hypertension still remains difficult to define. Immunosuppressive therapy, now including OKT3 monoclonal antibody in addition to conventional drugs and cyclosporine, lessened the frequency and severity of rejection and infection but still need improvements. Late graft arteriosclerosis remains a serious threat despite the use of retransplantation and, in some cases, mechanical cardiac support.

Adult↗
PubMed1989

[Cyclosporin and convulsions after cardiac transplantation].

6 p. 100 of a population of 129 heart transplant recipients presented isolated convulsions under cyclosporin (Ci) immunosuppressive treatment. These seizures were unexplained by acute causes, infectious or cerebro-vascular. Seizures started generally a few days after Ci therapy onset, and led often to severe convulsive states, with sometimes a status epilepticus. For most of them, Ci serum levels were within, or just above, the recommended therapeutic range. Ischemic brain damage that occurred prior to surgery and Ci therapy, could be a contributing factor to Ci-induced seizures in this population of heart transplant recipients.

Adolescent↗
PubMed1989

[Results of simultaneous myocardial and cerebral revascularization surgery].

Out of 3,678 patients who underwent aorto-coronary bypass between May, 1979 and October, 1987 at the La Pitié Hospital, Paris, 48 had simultaneous myocardial and cerebral revascularization. Operative mortality rate was 4.2 p. 100. Peri-operative myocardial infarction occurred in 3 cases (6.2 p. 100). No neurological complication was observed. The survival rate at 5 years (operative mortality included) was 74.8 +/- 8.66 p. 100. These results obtained in patients with multiple arterial disease are in agreement with those found in the literature. The lack of neurological complications is in favour of a systematic combined surgical treatment of severe carotid and coronary lesions.

Aged↗